Protalix BioTherapeutics, Inc. (DE) (PLX) Earnings Call Analysis

AMEX · Healthcare · Biotechnology

17/25

Growth 4 Margin 5 Expansion 3 Platform 2 Financial 3

latest quarter score

Earnings Reports

17
PLX Q2 2026: Elfabrio Sales Drive 29% Growth in Goods Revenue Amid Pipeline Advances
August 12, 2026
9
Protallix (PLX) Q1 2026: $25M Milestone Bolsters Cash, Sets Stage for Elfabio Uptake
May 13, 2026
17
Protallix (PLX) Q4 2025: $25M Milestone Bolsters Cash, EU Dosing Win Reshapes Fabry Trajectory
March 18, 2026
22
NOVA (NVMI) Q4 2024: Advanced Packaging Doubles to 15% of Product Revenue, Extending Share Gains
November 13, 2025
9
Protalix (PLX) Q2 2025: R&D Spend Doubles as PRX115 Phase II Launch Nears
August 14, 2025
10
Protalix BioTherapeutics (PLX) Q1 2025: Revenues Surge 170% Driven by Pfizer Sales, Phase II Trial Initiation Signals Pipeline Momentum
May 09, 2025
15
Protalix BioTherapeutics (PLX) FY 2024: 31% Revenue Growth Driven by Chiesi Partnership and Pipeline Progress
March 17, 2025

Browse all companies